GlassScriptPhysician profile
Marjorie Ann Malbas
NPI 1588977284
$221,902.07
in general payments reported to CMS, 2019-2025
47 companies · $69K in 2025
The $69K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $22K · 2021: $27K · 2022: $15K · 2023: $40K · 2024: $30K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110K · Travel and Lodging: $17K · Consulting Fee: $6,063 · Food and Beverage: $5,910 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,370.00 |
| Travel and Lodging | $16,988.24 |
| Consulting Fee | $6,062.50 |
| Food and Beverage | $5,909.89 |
| Education | $102.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $177,091.02 | 2019-2025 | Evenity, Prolia |
| Ascendis Pharma Endocrinology INC | $35,616.82 | 2024-2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $1,485.61 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,279.53 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $902.47 | 2019-2024 | Tymlos |
| Abbvie INC. | $513.16 | 2019-2022 | |
| Mannkind Corporation | $510.72 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $491.56 | 2019-2022 | |
| Lilly USA, LLC | $451.73 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $365.02 | 2019-2022 | |
| Kyowa Kirin, INC. | $335.41 | 2024 | Crysvita |
| Abbott Laboratories | $323.26 | 2019-2022 | |
| Amarin Pharma, INC. | $265.02 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $249.19 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.98 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjorie Ann Malbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.